coin-img-ETHETH+2.60%coin-img-BTCBTC+3.43%coin-img-SOLSOL+3.43%coin-img-XRPXRP+3.69%coin-img-ROBOROBO-0.05%coin-img-OPNOPN+3.27%coin-img-USDCUSDC-0.02%coin-img-NEXINEXI-33.65%coin-img-ETHETH+2.60%coin-img-BTCBTC+3.43%coin-img-SOLSOL+3.43%coin-img-XRPXRP+3.69%coin-img-ROBOROBO-0.05%coin-img-OPNOPN+3.27%coin-img-USDCUSDC-0.02%coin-img-NEXINEXI-33.65%coin-img-ETHETH+2.60%coin-img-BTCBTC+3.43%coin-img-SOLSOL+3.43%coin-img-XRPXRP+3.69%coin-img-ROBOROBO-0.05%coin-img-OPNOPN+3.27%coin-img-USDCUSDC-0.02%coin-img-NEXINEXI-33.65%coin-img-ETHETH+2.60%coin-img-BTCBTC+3.43%coin-img-SOLSOL+3.43%coin-img-XRPXRP+3.69%coin-img-ROBOROBO-0.05%coin-img-OPNOPN+3.27%coin-img-USDCUSDC-0.02%coin-img-NEXINEXI-33.65%
user-avatar
Tim Fries

BioNTech Stock Sinks Over 20% on March 10, 2026 After Q4 2025 Loss and Founder Exit Plan

On March 10, 2026, BioNTech's Nasdaq-listed shares dropped more than 20% after the company reported a wider-than-expected adjusted loss for Q4 2025 and issued weak 2026 revenue guidance. The selloff accelerated as investors reacted to news that co-founders Ugur Sahin and Özlem Türeci intend to leave their executive roles by the end of 2026 to lead a new mRNA-focused venture.
Selected
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
StocksTrading